10 June 2025
EMA/188361/2025 Rev. 1*
Committee for Medicinal Products for Human Use (CHMP)

Colchicine tablet 0.5 mg and 1 mg product-specific bioequivalence guidance

Draft Agreed by Pharmacokinetics Working Party (PKWP)	January 2019
Adopted by CHMP for release for consultation	28 February 2019
Start of public consultation	8 March 2019
End of consultation (deadline for comments)	30 June 2019
Draft Agreed by Pharmacokinetics Working Party (PKWP)	September 2019
Adopted by CHMP	19 September 2019
Date of coming into effect	1 April 2020
Draft revision agreed by Methodology Working Party (MWP)	3 April 2025
Adopted by CHMP	10 June 2025
Date of coming into effect	1 January 2026

* This revision relates to the deletion of the reference to high solubility in accordance with the ICH M13A guideline

Keywords	***Bioequivalence, generics, colchicine***

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Colchicine tablet 0.5 mg and 1 mg product-specific bioequivalence guidance

Disclaimer:

This guidance should not be understood as being legally enforceable and is without prejudice to the need to ensure that the data submitted in support of a marketing authorisation application complies with the appropriate scientific, regulatory and legal requirements.

Requirements for bioequivalence demonstration (MWP)*

BCS Classification**	**BCS Class:** ☐ **I** ☒ **III** ☐ **Neither of the two** **Background:** Colchicine is considered a high solubility compound with limited absorption.
Bioequivalence study design *in case a BCS biowaiver is not feasible or applied*	**single dose** **cross-over**
	healthy volunteers
	☒ **fasting** ☐ **fed** ☐ **both** ☐ **either fasting or fed**
	Strength: 1 mg. **Background:** Highest strength to be used for a drug with linear pharmacokinetics. **Number of studies:** One.

Analyte	☒ **parent** ☐ **metabolite** ☐ **both**
	☒ **plasma/serum** ☐ **blood** ☐ **urine**
	Enantioselective analytical method: ☐ **yes** ☒ **no**
Bioequivalence assessment	**Main pharmacokinetic variables:** C_{max} and AUC_{0-t}
	90% confidence interval: 80.00– 125.00% for C_{max} and 90.00-111.11% for AUC_{0-t}. **Background:** Colchicine is a narrow therapeutic index drug.

* As intra-subject variability of the reference product has not been reviewed to elaborate this product-specific bioequivalence guideline, it is not possible to recommend at this stage the use of a replicate design to demonstrate high intra-subject variability and widen the acceptance range of C_{max}. If high intra-individual variability (CV_{intra} > 30 %) is expected, the applicants might follow respective guideline recommendations.

** Applying for a BCS-based biowaiver is restricted to highly soluble drug substances with known human absorption and considered not to have a narrow therapeutic index (NTI). As colchicine is considered a NTI drug, a BCS biowaiver is not possible.